Golimumab - Inflammatory bowel disease

You are here : Home > Formulary Search > Golimumab - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines BNF SPC

ICB

NICE

Restrictions / Comments :

Documentation

NICE Technology Appraisal

NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Evidence Review

Biologic use for moderately to severely active ulcerative colitis - Evidence Review - May 2015

PAD Profile

ChemicalSubstance :

Golimumab

Indication :

Inflammatory bowel disease

Group Name :

Keywords :

IBD, biologics, biosimilars, high cost immunomodulator, Sequential use of biologic medicines ,TNF alpha inhibitor, Cytokine modulator, UC

Brand Names Include :

Simponi

Important Information :

Ulcerative Colitis in Adults only. Prescribe by brand.

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Inflammatory bowel disease

Supporting Documents :

Other Indications

Below are listed other indications that Golimumab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Inflammatory bowel disease.

Committee Recommendations (3)

02 Oct 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found on the IBD guidelines page.

05 Dec 18 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommends the sequential use of TNF alpha inhibitors (adalimumab, infliximab or golimumab) in patients with moderately to severely active ulcerative colitis prior to a switch to vedolizumab.

Adalimumab, Infliximab and Golimumab are payment by results excluded drugs and will be considered RED on the traffic light system.

Gastroenterology specialists will be required to complete blueteq initiation and continuation forms for the commissioners.

30 Sep 15 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN recommend the use of Adalimumab, Golimumab, Infliximab and Vedolizumab in line with NICE guidelines and a treatment pathway has been developed with local gastroenterologists.